AbCellera Biologics Inc

$5.09
Market Cap 1.54B
ROE -14.9%
Gross Margin 100.0%
Debt/Equity 0.1
Current Ratio 14.1
Revenue QoQ 96.3%
EPS QoQ -0.1%
F-Score 3

About

AbCellera discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners.

Exchange
NASDAQ
Sector
Financial Services
Industry
Banks - Regional

Sector context

Financial Services

Undervalued

Trading at a discount to sector peers

P/E
-11.10
vs median 7.16
P/B
1.70
vs median 0.99
ROE
-0.15
vs median 0.16

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics